Wanjin Hong
Wanjin Hong serves as our Independent Director. Professor Hong has more than 35 years of experience in biomedical research, scientific leadership and biotechnology collaboration.
Professor Hong is Chief Business Development Officer of the Biomedical Research Council at Singapore’s Agency for Science, Technology and Research (A*STAR), Research Director at the Institute of Molecular and Cell Biology (IMCB), and a tenured professor at the National University of Singapore (NUS). He served as Executive Director of IMCB from 2011 to 2023, advancing research capabilities, biotechnology ventures and pharmaceutical partnerships. Professor Hong is internationally recognised for his contributions to membrane trafficking and cancer signalling. His pioneering research on the Hippo pathway and YAP/TAZ–TEAD interactions helped lay the foundation for TEAD-targeted cancer therapies. He has authored over 300 scientific publications and received Singapore’s President’s Science and Technology Medal in 2022. He is also a Fellow of the Singapore National Academy of Science.
Professor Hong graduated from Xiamen University in 1982 and earned his PhD from the State University of New York at Buffalo, where he also completed his postdoctoral training.